← All trials
NCT06288373
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2024
- Primary completion
- Mar 1, 2031
- Completion date
- Mar 1, 2031
- First posted
- Mar 1, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Chinese Academy of Medical SciencesCollaborator
- Guangxi Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Shengjing HospitalCollaborator
- Sun Yat-Sen UniversityCollaborator
- Huazhong University of Science and TechnologySponsor investigator
- Central South UniversityCollaborator
- Shandong UniversityCollaborator
- Zhejiang UniversityCollaborator
- Sichuan UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- University of Electronic Science and Technology of ChinaCollaborator
- People's Liberation Army of ChinaCollaborator
- Anhui Medical UniversityCollaborator
- Gansu Provincial Maternity and Child-Care HospitalCollaborator
- Huazhong University of Science and TechnologyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.